Cargando…

Dasatinib-induced Reversible Demyelinating Peripheral Neuropathy and Successful Conversion to Nilotinib in Chronic Myelogenous Leukemia

Dasatinib, a tyrosine kinase inhibitor, is commonly used in the treatment of chronic myelogenous leukemia. A rare side effect is peripheral neuropathy. A 54-year-old woman experienced gradually accelerated dysesthesia and hypoesthesia in her extremities, 2 months following treatment with dasatinib....

Descripción completa

Detalles Bibliográficos
Autores principales: Inoue, Hiroyasu, Taji, Hirofumi, Yamada, Kentaro, Iriyama, Chisako, Saito, Touko, Kato, Harumi, Yanada, Masamitsu, Yamamoto, Kazuhito, Matsukawa, Noriyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7644482/
https://www.ncbi.nlm.nih.gov/pubmed/32611965
http://dx.doi.org/10.2169/internalmedicine.4824-20
_version_ 1783606466429583360
author Inoue, Hiroyasu
Taji, Hirofumi
Yamada, Kentaro
Iriyama, Chisako
Saito, Touko
Kato, Harumi
Yanada, Masamitsu
Yamamoto, Kazuhito
Matsukawa, Noriyuki
author_facet Inoue, Hiroyasu
Taji, Hirofumi
Yamada, Kentaro
Iriyama, Chisako
Saito, Touko
Kato, Harumi
Yanada, Masamitsu
Yamamoto, Kazuhito
Matsukawa, Noriyuki
author_sort Inoue, Hiroyasu
collection PubMed
description Dasatinib, a tyrosine kinase inhibitor, is commonly used in the treatment of chronic myelogenous leukemia. A rare side effect is peripheral neuropathy. A 54-year-old woman experienced gradually accelerated dysesthesia and hypoesthesia in her extremities, 2 months following treatment with dasatinib. Nerve conduction studies revealed a prolonged conduction velocity with temporal dispersion, indicating demyelinating peripheral neuropathy. After changing dasatinib to nilotinib, both her clinical symptoms and electrophysiological data gradually improved. We herein report the findings of this case with a review of the pertinent literature.
format Online
Article
Text
id pubmed-7644482
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher The Japanese Society of Internal Medicine
record_format MEDLINE/PubMed
spelling pubmed-76444822020-11-13 Dasatinib-induced Reversible Demyelinating Peripheral Neuropathy and Successful Conversion to Nilotinib in Chronic Myelogenous Leukemia Inoue, Hiroyasu Taji, Hirofumi Yamada, Kentaro Iriyama, Chisako Saito, Touko Kato, Harumi Yanada, Masamitsu Yamamoto, Kazuhito Matsukawa, Noriyuki Intern Med Case Report Dasatinib, a tyrosine kinase inhibitor, is commonly used in the treatment of chronic myelogenous leukemia. A rare side effect is peripheral neuropathy. A 54-year-old woman experienced gradually accelerated dysesthesia and hypoesthesia in her extremities, 2 months following treatment with dasatinib. Nerve conduction studies revealed a prolonged conduction velocity with temporal dispersion, indicating demyelinating peripheral neuropathy. After changing dasatinib to nilotinib, both her clinical symptoms and electrophysiological data gradually improved. We herein report the findings of this case with a review of the pertinent literature. The Japanese Society of Internal Medicine 2020-06-30 2020-10-01 /pmc/articles/PMC7644482/ /pubmed/32611965 http://dx.doi.org/10.2169/internalmedicine.4824-20 Text en Copyright © 2020 by The Japanese Society of Internal Medicine https://creativecommons.org/licenses/by-nc-nd/4.0/ The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Inoue, Hiroyasu
Taji, Hirofumi
Yamada, Kentaro
Iriyama, Chisako
Saito, Touko
Kato, Harumi
Yanada, Masamitsu
Yamamoto, Kazuhito
Matsukawa, Noriyuki
Dasatinib-induced Reversible Demyelinating Peripheral Neuropathy and Successful Conversion to Nilotinib in Chronic Myelogenous Leukemia
title Dasatinib-induced Reversible Demyelinating Peripheral Neuropathy and Successful Conversion to Nilotinib in Chronic Myelogenous Leukemia
title_full Dasatinib-induced Reversible Demyelinating Peripheral Neuropathy and Successful Conversion to Nilotinib in Chronic Myelogenous Leukemia
title_fullStr Dasatinib-induced Reversible Demyelinating Peripheral Neuropathy and Successful Conversion to Nilotinib in Chronic Myelogenous Leukemia
title_full_unstemmed Dasatinib-induced Reversible Demyelinating Peripheral Neuropathy and Successful Conversion to Nilotinib in Chronic Myelogenous Leukemia
title_short Dasatinib-induced Reversible Demyelinating Peripheral Neuropathy and Successful Conversion to Nilotinib in Chronic Myelogenous Leukemia
title_sort dasatinib-induced reversible demyelinating peripheral neuropathy and successful conversion to nilotinib in chronic myelogenous leukemia
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7644482/
https://www.ncbi.nlm.nih.gov/pubmed/32611965
http://dx.doi.org/10.2169/internalmedicine.4824-20
work_keys_str_mv AT inouehiroyasu dasatinibinducedreversibledemyelinatingperipheralneuropathyandsuccessfulconversiontonilotinibinchronicmyelogenousleukemia
AT tajihirofumi dasatinibinducedreversibledemyelinatingperipheralneuropathyandsuccessfulconversiontonilotinibinchronicmyelogenousleukemia
AT yamadakentaro dasatinibinducedreversibledemyelinatingperipheralneuropathyandsuccessfulconversiontonilotinibinchronicmyelogenousleukemia
AT iriyamachisako dasatinibinducedreversibledemyelinatingperipheralneuropathyandsuccessfulconversiontonilotinibinchronicmyelogenousleukemia
AT saitotouko dasatinibinducedreversibledemyelinatingperipheralneuropathyandsuccessfulconversiontonilotinibinchronicmyelogenousleukemia
AT katoharumi dasatinibinducedreversibledemyelinatingperipheralneuropathyandsuccessfulconversiontonilotinibinchronicmyelogenousleukemia
AT yanadamasamitsu dasatinibinducedreversibledemyelinatingperipheralneuropathyandsuccessfulconversiontonilotinibinchronicmyelogenousleukemia
AT yamamotokazuhito dasatinibinducedreversibledemyelinatingperipheralneuropathyandsuccessfulconversiontonilotinibinchronicmyelogenousleukemia
AT matsukawanoriyuki dasatinibinducedreversibledemyelinatingperipheralneuropathyandsuccessfulconversiontonilotinibinchronicmyelogenousleukemia